In “interventional glaucoma,” glaucoma is treated with minimally invasive surgeries or interventional procedures much earlier in the disease process. It is a shift away from the way glaucoma was treated years ago, which typically began with eyedrops and only progressed to surgery at the middle or end of the disease progression. Interventional glaucoma intervenes earlier in the treatment process.
Nathan M. Radcliffe, M.D. is a highly-experienced glaucoma and cataract surgeon. He was the Director of the Glaucoma Services at Cornell, and then NYU and Bellevue Hospital, and currently is Associate Clinical Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai. Dr. Radcliffe is unique because he is active in both academic and private practice settings. He is a microincisional glaucoma surgery (MIGS) innovator and instructor and is the Chief Editor of the publication Glaucoma Physician.
Dr. Radcliffe was the first surgeon in New York to offer patients the CyPass Supraciliary Microstent, the Kahook Dual Blade Goniotomy, Visco 360 and Trab 360, the G6 micropulse laser, and Allergan’s Xen subconjunctival implant.
Dr. Radcliffe has managed some of the most difficult glaucoma and cataract cases from all over the world and is truly able to offer a tailored glaucoma and cataract surgery to his patients, being able to perform all of the available glaucoma surgeries that are currently FDA approved, and knowing the procedures and the efficacy and safety data well enough to correlate the optimal procedure with the patient’s disease.